Posted by Michael Wonder on 07 Jun 2026
Boan Biotech submits a biologics license application for two denosumab biosimilars in the US
29 May 2026 - Boan Biotech announced today that it has submitted a biologics license application to the US FDA for its two biosimilars: BA6101 (denosumab injection 60 mg) and BA1102 (denosumab injection 120 mg).
This submission marks a milestone in the company’s efforts to accelerate the global expansion of its core products.
